News and Trends 18 Dec 2019 Cellestia Secures €18M to Develop First-in-Class Cancer Drug Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […] December 18, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2019 Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […] December 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2019 Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease A treatment developed by the Irish company Amarin has become the first FDA-approved drug to lower the risk of strokes and heart attacks when combined with statins in patients with high levels of circulating fat molecules called triglycerides. To be eligible for Vascepa, patients must also either have established cardiovascular disease, or type 2 diabetes […] December 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2019 Transgene’s Cancer Vaccine Abandoned after Phase II Fail French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […] December 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2019 Iterum Therapeutics Reels from Antibiotic Phase III Fail An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […] December 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2019 €14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […] December 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […] December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2019 Scientists Use DNA Data Storage to Hide Information in Everyday Objects Scientists have developed a method for storing DNA data in 3D-printed objects, which could one day allow machines to replicate themselves. The group, based at ETH Zurich, Switzerland, as well as in Israel and the US, began by synthesizing DNA molecules that encode blueprints of the Stanford bunny, a rabbit-shaped object commonly used in testing […] December 9, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Update: Cancer Immunotherapy Biotech Files for Insolvency Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […] December 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Dutch Startup Gets €9M to Create First Lab-Grown Pork Prototype Dutch startup Meatable has raised €9M in a seed round that will allow the company to host a tasting of its first prototype of lab-grown pork by summer 2020. The fundraising was led by the German VC BlueYard Capital, which had participated in Meatable’s previous €3M round last year. New investors include business angels Albert […] December 6, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […] December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2019 €31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes The French biotech Diabeloop has raised €31M to launch an artificial pancreas device designed to automatically control the blood glucose levels of type 1 diabetes patients. According to Diabeloop, this is the biggest Series B round raised by a European company developing therapies that use artificial intelligence. The round was led by the French family […] December 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email